|
|
Article: Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings.
- Article from:
- PR Newswire
- Article date:
- May 30, 2008
|
Copyright informationCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Trial Demonstrates Safety and Preliminary Efficacy and Supports Further Clinical Development of tgAAC94
BOSTON and SEATTLE, May 30 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation issued a news release earlier today, entitled "Targeted Genetics Reports Additional Data From Inflammatory Arthritis Clinical Trial," announcing additional interim data from its Phase 1/2 clinical study of tgAAC94 in patients with inflammatory arthritis. Pervin Anklesaria, Ph.D., vice president of therapeutic development for Targeted Genetics, presented the data in an oral presentation at the 11th Annual Meeting of the American Society of Gene Therapy (ASGT) in Seattle.
To clarify, ...
Related newspaper, magazine, and journal articles:
|
|
Article: Targeted Genetics Reports Second Quarter 1999 Financial Results.
PR Newswire;
July 29, 1999 ;
700+ words
......30, 1999, the Company's cash, cash equivalents...30, 1999, the Company announced the...owned 80.1 by Targeted Genetics. Emerald's initial...executive officer of Targeted Genetics. While we negotiated...Alkermes. The company also appointed...rest of the year. Targeted ...
|
|